The company shall process the change of name application with BSE Ltd. in due course
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The company operates a chain of mid-sized multi-speciality hospitals
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Subscribe To Our Newsletter & Stay Updated